Higgins John L's Form 4 filing
Ligand Pharmaceuticals Inc (LGND) · filed Nov 21, 2022
- Accession no.
- 0000899243-22-036575
- Filed
- Nov 21, 2022
- Trade date
- Nov 17-18, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $783.2K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Higgins John LCIK 0001208906 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 17, 2022 | Common Stock | SSaleDisposed | −10,000 | $78.32 | −$783,200 | 416,731 | Direct | |
| Nov 18, 2022 | Common Stock | MOption exerciseAcquired | +10,000 | $12.78 | +$127,800 | 426,731 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 18, 2022 | Common Stock | MOption exerciseDisposed | −10,000 | $0.00 | $0 | 40,335 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.